Hospital
Ohio County Hospital Corporation
Ohio County Hospital Corporation was paid $34.61M by Medicaid between Jan 2018 and Dec 2024, across 322 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoOHIO COUNTY HOSPITAL CORPORATION
HARTFORD, KY 42347
HARTFORD, KY 42347
33aNPI1629007430assigned 07/02/2006
33bProvider typeCritical Access Hospital
28Total paid$34.61M
24GClaims916,469
24DCodes billed322
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#2 of 16
Median peer was paid$11.73M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAUGHERTY, JENNIFER controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 134,775 | $4.00M | |
| 2019 | 137,437 | $4.26M | |
| 2020 | 116,519 | $3.70M | |
| 2021 | 141,623 | $5.26M | |
| 2022 | 150,494 | $5.99M | |
| 2023 | 134,709 | $6.16M | |
| 2024incomplete | 100,912 | $5.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 21,814 | 18,408 | $3.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 13,458 | 11,095 | $3.09M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.9% | 79,414 | 64,985 | $2.37M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.4% | 42,449 | 36,625 | $1.52M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 3,409 | 2,920 | $1.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 5,141 | 3,700 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 2,996 | 2,622 | $1.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 4,040 | 3,343 | $917K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.5% | 15,492 | 3,684 | $859K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.4% | 10,820 | 9,501 | $844K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 10,022 | 2,935 | $608K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 10,336 | 8,443 | $598K |
310 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 16,557 | $554K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,085 | $549K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 43,521 | $509K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 6,929 | $492K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 8,161 | $490K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 4,484 | $450K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 5,270 | $439K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 17,121 | $430K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 8,947 | $425K |
| 80053 | Comprehensive metabolic panel | 1.1% | 42,020 | $385K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 353 | $376K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.0% | 294 | $350K |
| 36415 | Collection of venous blood by venipuncture | <1% | 78,944 | $343K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,826 | $337K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,015 | $334K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,958 | $320K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,747 | $286K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17,969 | $257K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,056 | $251K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,737 | $247K |
| 20610 | <1% | 1,777 | $246K | |
| 80061 | Lipid panel | <1% | 14,452 | $237K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,371 | $231K |
| G0378 | Hospital observation service, per hour | <1% | 1,160 | $228K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,010 | $222K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,060 | $208K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,069 | $206K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,312 | $198K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,184 | $196K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,967 | $192K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,824 | $169K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,105 | $165K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,988 | $164K |
| 73630 | <1% | 2,432 | $163K | |
| 80050 | General health panel | <1% | 5,061 | $149K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,086 | $146K |
| 96376 | <1% | 1,940 | $145K | |
| 73610 | <1% | 2,195 | $144K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,291 | $141K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,045 | $140K |
| 73562 | <1% | 1,925 | $137K | |
| 73030 | <1% | 2,218 | $135K | |
| 72110 | <1% | 1,645 | $133K | |
| 87634 | <1% | 1,981 | $122K | |
| 95117 | <1% | 5,888 | $107K | |
| 72100 | <1% | 1,349 | $106K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 199 | $105K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 2,226 | $98K |
| 73130 | <1% | 1,483 | $98K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,019 | $98K |
| 74018 | <1% | 1,733 | $91K | |
| 84436 | <1% | 9,379 | $87K | |
| 97161 | <1% | 1,255 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 457 | $83K |
| 84484 | <1% | 5,988 | $83K | |
| 84479 | <1% | 9,067 | $80K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,463 | $71K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 837 | $71K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,064 | $70K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,871 | $69K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,899 | $68K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,765 | $68K |
| 82607 | <1% | 6,166 | $68K | |
| 83880 | <1% | 3,042 | $67K | |
| 73110 | <1% | 872 | $67K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 318 | $63K |
| 74022 | <1% | 904 | $61K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,404 | $60K |
| 80074 | <1% | 1,316 | $59K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 653 | $58K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 158 | $58K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 849 | $58K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 195 | $57K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,623 | $57K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 674 | $56K |
| 87186 | <1% | 4,060 | $52K | |
| 85610 | <1% | 4,026 | $52K | |
| 82728 | <1% | 3,812 | $51K | |
| 86003 | <1% | 831 | $51K | |
| 73564 | <1% | 770 | $50K | |
| 74019 | <1% | 732 | $50K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 198 | $50K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,513 | $47K |
| 83735 | <1% | 7,662 | $45K | |
| 81003 | <1% | 9,674 | $45K | |
| 81001 | <1% | 8,360 | $44K | |
| 87070 | <1% | 4,545 | $42K | |
| 83690 | <1% | 6,301 | $42K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,231 | $39K |
| 82746 | <1% | 3,707 | $39K | |
| 92557 | <1% | 760 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,430 | $38K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,254 | $38K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,774 | $37K |
| 82150 | <1% | 5,178 | $36K | |
| 81025 | <1% | 3,479 | $35K | |
| 86140 | <1% | 2,966 | $34K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 57 | $34K |
| 82553 | <1% | 1,632 | $33K | |
| 87077 | <1% | 2,402 | $33K | |
| 85379 | <1% | 3,072 | $31K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,018 | $31K |
| 83550 | <1% | 3,575 | $29K | |
| 76830 | Ultrasound, transvaginal | <1% | 143 | $29K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,246 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 282 | $27K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,105 | $26K |
| 83540 | <1% | 3,872 | $24K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 974 | $24K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,371 | $23K |
| 87088 | <1% | 3,055 | $23K | |
| 87040 | <1% | 1,165 | $22K | |
| 80305 | <1% | 1,633 | $22K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,402 | $21K |
| 76536 | <1% | 119 | $21K | |
| 86695 | <1% | 970 | $21K | |
| 86696 | <1% | 954 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,206 | $20K |
| 78227 | <1% | 37 | $19K | |
| 84703 | <1% | 2,005 | $19K | |
| 71250 | <1% | 77 | $19K | |
| 90715 | <1% | 617 | $18K | |
| C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable) | <1% | 27 | $18K |
| 94664 | <1% | 518 | $17K | |
| 82550 | <1% | 2,797 | $17K | |
| 86704 | <1% | 1,387 | $17K | |
| 86708 | <1% | 1,402 | $16K | |
| 99152 | <1% | 687 | $16K | |
| 90656 | <1% | 1,479 | $16K | |
| 86706 | <1% | 1,422 | $16K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,941 | $16K |
| 84439 | <1% | 1,252 | $15K | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 43 | $15K |
| 87073 | <1% | 1,760 | $15K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 292 | $13K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 705 | $13K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 150 | $13K |
| 47562 | <1% | 15 | $13K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 678 | $12K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 546 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 593 | $12K |
| 99442 | <1% | 1,158 | $12K | |
| 73502 | <1% | 206 | $12K | |
| 87205 | <1% | 1,883 | $12K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 375 | $12K |
| 77080 | <1% | 116 | $12K | |
| 73080 | <1% | 219 | $11K | |
| 97162 | <1% | 163 | $11K | |
| 82962 | <1% | 2,617 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,062 | $11K |
| 82803 | <1% | 364 | $11K | |
| 0012A | <1% | 611 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,752 | $10K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 565 | $10K |
| 87430 | <1% | 686 | $10K | |
| 90461 | <1% | 1,244 | $10K | |
| 92567 | <1% | 1,107 | $10K | |
| 71101 | <1% | 149 | $10K | |
| 85651 | <1% | 1,816 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 567 | $9K |
| 0011A | <1% | 693 | $8K | |
| 73100 | <1% | 126 | $8K | |
| 12001 | <1% | 104 | $8K | |
| 84702 | <1% | 511 | $8K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 686 | $8K |
| 84403 | <1% | 418 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,642 | $8K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 60 | $8K |
| 96127 | <1% | 2,028 | $8K | |
| 30802 | <1% | 13 | $7K | |
| 87807 | <1% | 442 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,382 | $7K |
| 99153 | Mod sedat endo service >5yrs | <1% | 214 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,343 | $7K |
| 99443 | <1% | 472 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 926 | $6K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 588 | $6K |
| 36600 | <1% | 303 | $6K | |
| 88342 | <1% | 62 | $6K | |
| 36000 | <1% | 445 | $5K | |
| 86308 | <1% | 755 | $5K | |
| 85730 | <1% | 332 | $5K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 12 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,225 | $5K |
| 62323 | <1% | 14 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 482 | $5K |
| 93971 | <1% | 26 | $5K | |
| 97165 | <1% | 94 | $5K | |
| 84550 | <1% | 1,028 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,611 | $4K |
| 86592 | <1% | 979 | $4K | |
| 82652 | <1% | 169 | $4K | |
| 86757 | <1% | 137 | $4K | |
| 86803 | <1% | 386 | $4K | |
| 72040 | <1% | 49 | $4K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 57 | $4K |
| 73090 | <1% | 53 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 31 | $4K |
| 72131 | <1% | 14 | $4K | |
| 0001A | <1% | 168 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $4K |
| 88304 | <1% | 105 | $4K | |
| 83605 | <1% | 561 | $4K | |
| 99243 | <1% | 113 | $3K | |
| 99406 | <1% | 1,462 | $3K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 246 | $3K |
| 92523 | <1% | 15 | $3K | |
| 86618 | <1% | 155 | $3K | |
| 82043 | <1% | 734 | $3K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 120 | $3K |
| 0002A | <1% | 127 | $3K | |
| 99441 | <1% | 298 | $3K | |
| 0013A | <1% | 149 | $2K | |
| 95886 | <1% | 15 | $2K | |
| 94060 | <1% | 16 | $2K | |
| 86665 | <1% | 47 | $2K | |
| 73590 | <1% | 39 | $2K | |
| 73120 | <1% | 25 | $2K | |
| 88142 | <1% | 137 | $2K | |
| 82570 | <1% | 629 | $2K | |
| 72050 | <1% | 25 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 133 | $2K |
| 87340 | <1% | 310 | $2K | |
| 76770 | <1% | 14 | $2K | |
| 86235 | <1% | 13 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 61 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 177 | $2K |
| 93226 | <1% | 14 | $2K | |
| 83525 | <1% | 183 | $2K | |
| 95816 | <1% | 13 | $2K | |
| 72072 | <1% | 29 | $2K | |
| 94729 | <1% | 16 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $2K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 165 | $1K |
| 94727 | <1% | 16 | $1K | |
| 73560 | <1% | 24 | $1K | |
| 69209 | <1% | 38 | $1K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 13 | $1K |
| 73140 | <1% | 29 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 63 | $1K |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 32 | $1K |
| 87420 | <1% | 61 | $1K | |
| 95115 | <1% | 61 | $1K | |
| 83516 | <1% | 27 | $1K | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 163 | $1K |
| 90649 | <1% | 154 | $1K | |
| 93225 | <1% | 14 | $1K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 24 | $936.52 |
| 86645 | <1% | 36 | $936.32 | |
| 82565 | <1% | 191 | $909.19 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 29 | $908.84 |
| 86664 | <1% | 47 | $906.82 | |
| 86663 | <1% | 47 | $826.52 | |
| 90734 | <1% | 187 | $785.40 | |
| 86644 | <1% | 36 | $779.81 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 53 | $736.98 |
| 90670 | <1% | 39 | $696.90 | |
| 83001 | <1% | 47 | $668.73 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 328 | $646.58 |
| 83970 | <1% | 23 | $605.55 | |
| 87324 | <1% | 46 | $564.11 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 21 | $510.18 |
| 88738 | <1% | 26 | $492.98 | |
| 93242 | <1% | 13 | $479.69 | |
| 87045 | <1% | 51 | $463.57 | |
| 84402 | <1% | 28 | $459.60 | |
| 86430 | <1% | 54 | $448.82 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 76 | $409.76 |
| 87230 | <1% | 29 | $386.40 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 31 | $384.35 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $362.27 |
| 87427 | <1% | 41 | $342.68 | |
| 85652 | <1% | 119 | $325.65 | |
| 84520 | <1% | 98 | $319.92 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 20 | $310.20 |
| 87046 | <1% | 42 | $292.30 | |
| 0064A | <1% | 12 | $280.25 | |
| 87075 | <1% | 27 | $271.97 | |
| 80076 | <1% | 33 | $266.95 | |
| 51702 | <1% | 12 | $262.53 | |
| 86225 | <1% | 13 | $243.06 | |
| 88300 | <1% | 14 | $230.15 | |
| 94010 | <1% | 13 | $223.68 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 20 | $212.10 |
| 90662 | <1% | 67 | $188.20 | |
| 90480 | <1% | 13 | $185.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 72 | $168.68 |
| 82947 | <1% | 32 | $155.63 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 14 | $154.75 |
| 88740 | <1% | 22 | $154.10 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $140.16 |
| 90633 | <1% | 170 | $130.20 | |
| 87209 | <1% | 12 | $126.14 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 31 | $126.10 |
| 87177 | <1% | 12 | $114.94 | |
| 86705 | <1% | 12 | $106.92 | |
| 99407 | <1% | 22 | $97.07 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 13 | $75.24 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 67 | $69.60 |
| 87210 | <1% | 14 | $54.18 | |
| 84156 | <1% | 14 | $42.11 | |
| 90836 | <1% | 45 | $32.24 | |
| 84132 | <1% | 15 | $31.27 | |
| G0008 | Administration of influenza virus vaccine | <1% | 16 | $17.49 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| 90710 | 0% | 19 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 4,393 | $0.00 |
| 91301 | 0% | 173 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAUGHERTY, JENNIFER (PFS DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Ohio County Hospital Corporation | Hartford, KY | $2.15M |
| Ohio County Hospital Corporation | Beaver Dam, KY | $1.04M |
| Ohio County Hospital Corporation | Hartford, KY | $708K |
| Ohio County Hospital Corporation | Morgantown, KY | $666K |
| Ohio County Hospital Corporation | Hartford, KY | $638K |
| Ohio County Hospital Corporation | Hartford, KY | $509K |
| Ohio County Hospital Corporation | Fordsville, KY | $225K |
| Ohio County Hospital Corporation | Beaver Dam, KY | $88K |
| Ohio County Hospital Corporation | Owensboro, KY | $52K |
| Ohio County Hospital Corporation | Owensboro, KY | $14K |
| Ohio County Hospital Corporation | Owensboro, KY | $5K |
| Ohio County Hospital Corporation | Hartford, KY | $4K |
| Ohio County Hospital Corporation | Hartford, KY | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.